Amicus Therapeutics, Inc. (FOLD)

Market Cap	1.88B
Revenue (ttm)	543.14M
Net Income (ttm)	-29.37M
Shares Out	307.93M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	15.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,120,129
Open	6.01
Previous Close	5.95
Day's Range	5.97 - 6.15
52-Week Range	5.51 - 12.65
Beta	0.51
Analysts	Buy
Price Target	16.22 (+165.9%)
Earnings Date	Aug 7, 2025

About FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 31, 2007
• Employees: 499
• Stock Exchange: NASDAQ
• Ticker Symbol: FOLD
• Website: https://amicusrx.com

Financial Performance

In 2024, Amicus Therapeutics's revenue was $528.30 million, an increase of 32.29% compared to the previous year's $399.36 million. Losses were -$56.11 million, -62.99% less than in 2023.

Analyst Summary

According to 10 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price target is $16.22, which is an increase of 165.90% from the latest price.

Price Target

$16.22

(165.90% upside)

Analyst Consensus: Buy